Janux Therapeutics

#Bristol Myers Squibb #Collaboration #Janux Therapeutics #Oncology #Solid tumours

Janux and Bristol Myers Squibb partner on tumour-activated therapeutic

Bristol Myers Squibb and immunotherapy developer Janux Therapeutics have announced a collaboration and exclusive worldwide license agreement.   Under the terms of the agreement, the companies will develop an undisclosed, novel, tumour-activated therapeutic targeting a validated solid tumour antigen expressed across several human cancer types.  Janux may receive up to $50… Read More

#Business & Investment #Cancer Research #News